Clinical assessment of hydrogen-rich water and oxycodone hydrochloride controlled-release tablets in the treatment of malignant neuropathic pain

Abstract

Objective To investigate the clinical efficacy of hydrogen-rich water (HRW) combined with oxycodone hydrochloride controlled-release tablets (OHCT) in the treatment of malignant neuropathic pain (MNP) patients. Methods Eighty MNP patients were randomly divided into two groups: OHCT group (group A, n=40) and HRW combined OHCT group (group B, n=40). The visual analog scale (VAS) score, frequency of pain outbreaks, pain relief rate, average dose of OHCT per day, and adverse reactions were observed. Results The VAS scores and frequency of pain outbreaks in groups A and B were significantly reduced after treatment (P<0.05). Compared to group A, the VAS scores, pain relief rate, outbreak pain and average dose of OHCT per day in group B were significantly improved after 14 and 28 days of treatment (P<0.05), and the adverse reactions, such as constipation, nausea and vomiting, in group B were significantly less than those in group A (P<0.05). Conclusions HRW combined with OHCT can effectively improve the MNP, and reduce average dose of OHCT per day and adverse reactions. Key words: Hydrogen/AD; Oxycodone/AD; Pain, intractable/ET/DT; Neoplasms/CO/DT